Analysis of intellectual property strategies across different categories of digital therapeutics
-
By
-
Tomoki Maeda
-
Hiroshi Suzuki
-
Chikako Saotome
-
March 9, 2026
-
Clinical Scorecard: Evaluation of Intellectual Property Approaches in Various Types of Digital Therapeutics
At a Glance
| Category | Detail |
|---|
| Condition | Digital therapeutics (DTx) for treatment and prevention of various diseases, including mental health disorders |
| Key Mechanisms | Evidence-based interventions delivered via digital platforms, including apps, devices, and entertainment-based modalities |
| Target Population | Patients requiring digital therapeutic interventions, including those with psychiatric and other medical conditions |
| Care Setting | Digital healthcare environments utilizing app-based, device-based, and entertainment-based therapeutic products |
Key Highlights
- DTx products are categorized into app-based, app + device-based, and entertainment-based types with distinct IP strategies.
- Half of app-based DTx lack patent applications, whereas all app + device-based DTx have patents covering programs, biometric acquisition, and platform technology.
- Design rights are rarely used and limited in scope across DTx products, with only 5 of 30 products protected by design rights.
Guideline-Based Recommendations
Diagnosis
- Not applicable; focus is on IP strategy rather than clinical diagnosis.
Management
- Developers should tailor intellectual property strategies based on DTx product architecture to support innovation and development costs.
- Patent protection is essential for covering technological innovations, especially in app + device-based and entertainment-based DTx.
- Design rights may be considered but currently have limited practical utility in protecting DTx products.
Monitoring & Follow-up
- Monitor patent landscapes and design registrations relevant to DTx categories to inform strategic IP decisions.
Risks
- Lack of appropriate IP protection may hinder sustainable innovation and partnerships with larger pharmaceutical companies.
- Limited use of design rights may expose aesthetic aspects of DTx products to imitation.
Patient & Prescribing Data
Patients using digital therapeutics across various disease areas, including mental health and chronic conditions
DTx products require regulatory approval demonstrating efficacy and safety; IP protection supports clinical trial investments and market sustainability.
Clinical Best Practices
- Classify DTx products by components (app-based, app + device-based, entertainment-based) to guide IP strategy.
- Prioritize patent applications for technological innovations, especially in combined app and device products.
- Consider design rights selectively, recognizing their current limited scope in DTx protection.
- Leverage IP rights to facilitate alliances with pharmaceutical companies and secure R&D resources.
References
